Lecanemab for Alzheimer's Disease
(DIAN-TU Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progression compared to external controls, if amyloid plaque as measured by amyloid PET can be fully removed in DIAD, and the effects of amyloid removal on biomarkers of disease progression.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are on full anticoagulation or high-dose antiplatelet therapy, you may not be eligible to participate.
What is known about the safety of lecanemab for Alzheimer's disease?
Lecanemab has been studied for safety in people with early Alzheimer's disease. Some side effects include amyloid-related imaging abnormalities (ARIA), which are usually not serious but can be in rare cases, and infusion reactions. People taking blood thinners may have a higher risk of bleeding, and those with a specific gene (APOE4) may have a higher risk of ARIA.12345
Who Is on the Research Team?
Randall J Bateman, MD
Principal Investigator
Washington University School of Medicine
Are You a Good Fit for This Trial?
This trial is for individuals with a genetic form of Alzheimer's disease (DIAD) who were previously part of the DIAN-TU-001 study. Participants must carry specific mutations linked to early-onset Alzheimer's and are willing to undergo treatment with lecanemab.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive open-label lecanemab administered intravenously approximately every 2 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
What Are the Treatments Tested in This Trial?
Interventions
- lecanemab
lecanemab is already approved in United States, China for the following indications:
- Alzheimer's disease in the earliest symptomatic stages
- Mild cognitive impairment due to Alzheimer’s disease and mild AD dementia
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
Alzheimer's Association
Collaborator
Eisai Inc.
Industry Sponsor
Lynn Kramer
Eisai Inc.
Chief Medical Officer since 2019
MD
Tatsuyuki Yasuno
Eisai Inc.
Chief Executive Officer since 2023
MBA from Kellogg School of Management, Northwestern University; Bachelor of Political Science from Waseda University